# CGM Use in Heart Failure

Study · id `cardio:ct-nct07045298` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07045298](<https://clinicaltrials.gov/study/NCT07045298>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07045298

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT07045298. Randomized; no masking; primary purpose diagnostic. Start 2026-11 (anticipated); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT07045298, source copy `cardio:ctgov-nct07045298-2026-07-22`, retrieved 2026-10-26)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07045298, source copy `cardio:ctgov-nct07045298-2026-07-22`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07045298, source copy `cardio:ctgov-nct07045298-2026-07-22`, retrieved 2026-10-26)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07045298, source copy `cardio:ctgov-nct07045298-2026-07-22`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07045298, source copy `cardio:ctgov-nct07045298-2026-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07045298-2026-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: CGM Use in Heart Failure
- Condition: Heart Failure
- Condition: Diabetes Mellitus
- Intervention (Device): Libre 2 rt-CGM
- Intervention (Diagnostic test): POC BG + Blinded CGM
- Lead sponsor: Emory University
- Lead sponsor class: OTHER
- Collaborator: American Heart Association
- Collaborator class: OTHER
- Collaborator: Abbott Diabetes Care
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)
- Registry lists this organization as a collaborator: American Heart Association (`core:aha`)
- Registry lists this organization as a collaborator: Abbott Diabetes Care (`cardio:org-abbott-diabetes-care`)

## Provenance

Content hash: 48431772ca0e5b3129e7a59c7ce33619d7a00406bf8257a181ec22f7648da8cd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
